Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (ALT)
NASDAQ:ALT
Total Valuation
Altimmune has a market cap or net worth of $274.14M. The enterprise value is $229.46M.
Market Cap$274.14M
Enterprise Value$229.46M
Share Statistics
Altimmune has 81,106,970 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding81,106,970
Owned by Insiders0.86%
Owned by Institutions0.10%
Financial Efficiency
Altimmune’s return on equity (ROE) is -0.77 and return on invested capital (ROIC) is -79.91%.
Return on Equity (ROE)-0.77
Return on Assets (ROA)-0.68
Return on Invested Capital (ROIC)-79.91%
Return on Capital Employed (ROCE)-0.80
Revenue Per Employee338.98
Profits Per Employee-1.61M
Employee Count59
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Altimmune is ―. Altimmune’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value4.14
Price to FCF0.00
Price to Operating Cash Flow-3.79
PEG Ratio―
Income Statement
In the last 12 months, Altimmune had revenue of 20.00K and earned -95.06M in profits. Earnings per share was -1.34.
Revenue20.00K
Gross Profit20.00K
Operating Income-103.17M
Pretax Income-95.06M
Net Income-95.06M
EBITDA-94.81M
Earnings Per Share (EPS)-1.34
Cash Flow
In the last 12 months, operating cash flow was -4.91M and capital expenditures -92.27B, giving a free cash flow of -92.27B billion.
Operating Cash Flow-4.91M
Free Cash Flow-92.27B
Free Cash Flow per Share-1.14K
Dividends & Yields
Altimmune pays an annual dividend of $873, resulting in a dividend yield of ―
Dividend Per Share$873
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.03
52-Week Price Change-42.63%
50-Day Moving Average4.85
200-Day Moving Average6.11
Relative Strength Index (RSI)39.54
Average Volume (3m)4.56M
Important Dates
Altimmune upcoming earnings date is Nov 11, 2025, TBA (Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateNov 11, 2025
Ex-Dividend DateFeb 06, 2017
Financial Position
Altimmune as a current ratio of 13.11, with Debt / Equity ratio of 0.00%
Current Ratio13.11
Quick Ratio13.11
Debt to Market Cap0.00
Net Debt to EBITDA0.37
Interest Coverage Ratio-11.46K
Taxes
In the past 12 months, Altimmune has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Altimmune EV to EBITDA ratio is -5.03, with an EV/FCF ratio of -5.97.
EV to Sales23.83K
EV to EBITDA-5.03
EV to Free Cash Flow-5.97
EV to Operating Cash Flow-5.97
Balance Sheet
Altimmune has $149.83M in cash and marketable securities with $1.59M in debt, giving a net cash position of -$148.24M billion.
Cash & Marketable Securities$149.83M
Total Debt$1.59M
Net Cash-$148.24M
Net Cash Per Share-$1.83
Tangible Book Value Per Share$1.74
Margins
Gross margin is -205.00%, with operating margin of -515860.00%, and net profit margin of -475295.00%.
Gross Margin-205.00%
Operating Margin-515860.00%
Pretax Margin-475295.00%
Net Profit Margin-475295.00%
EBITDA Margin-474060.00%
EBIT Margin-475250.00%
Analyst Forecast
The average price target for Altimmune is $19.22, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$19.22
Price Target Upside468.64% Upside
Analyst ConsensusModerate Buy
Analyst Count11
Revenue Growth Forecast-95.12%
EPS Growth Forecast21.09%